CClinicalTrials.gg
CompletedNCT04334603EXIT-HFUpdated Feb 23, 2023

EXercise InTervention in Heart Failure

An interventional study of Exercise Training Program in Heart Failure, sponsored by Centro Hospitalar do Porto. Completed at 1 site in Portugal. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-23.

Sponsored by Centro Hospitalar do Porto · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a pragmatic, non-inferiority clinical trial, enrolling heart failure patients who will be randomized to a 12-week exercise training program either centre-based or home-based with telemonitoring. The impact of this intervention will be assessed on established surrogate markers in HF such as maximal exercise capacity, plasma biomarkers and quality of life. The cost-effectiveness and overall satisfaction with the treatment will also be studied. In addition to measure the clinical and economic impact of this innovative way of delivering exercise, it is intended to unravel new molecular pathways and assess a pool of biomarkers that provide a wide mechanistic picture underlying the clinical effects of exercise.

02

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • Heart failure
  • Home-based exercise
  • Maximal oxygen consumption
  • Cost-effectiveness
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Diagnosis of HFrEF and HFpEF according to criteria of the European Society of Cardiology (2016)
  2. Clinical stability for ≥ 6 weeks
  3. Optimal medical treatment for ≥ 6 weeks
  4. Patients that are able to understand and follow the exercise prescription
  5. Written informed consent

Exclusion criteria

Exclusion Criteria:

  1. Patients who have undertaken cardiac rehabilitation within the past 12 months
  2. Patients who have received an intracardiac defibrillator (ICD), Cardiac 3. Resynchronisation therapy (CRT) or combined CRT/ICD device implanted in the last 6 weeks
  3. Inability to exercise or conditions that may interfere with exercise intervention
  4. Signs of ischemia during cardiopulmonary exercise test
  5. Comorbidity that may influence one-year prognosis
  6. Symptomatic and/or exercise induced cardiac arrhythmia or conduction disturbances
  7. Currently pregnant or intend to become pregnant in the next year
  8. Expectation of receiving a cardiac transplant in the next 6 months
  9. Participation in another clinical trial
  10. Patients who are unable to understand the study information or unable to complete the outcome questionnaires
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Home-based exercise training

    The 12-week exercise-training program will include two sessions of combined exercise training per week, performed at home

    Other: Exercise Training Program

  • Active comparator
    Clinical-based exercise training

    The 12-week exercise-training program will include two sessions of combined exercise training per week, performed at the hospital

    Other: Exercise Training Program

Interventions

  • OtherExercise Training Program

    The 12-week exercise-training program will include two sessions of combined exercise training per week, performed at the hospital or at home.

05

What researchers measure

Primary outcomes

  1. Peak oxygen uptake (ml/kg/min)

    Patients will be submitted to cardiopulmonary treadmill exercise tests at baseline and after 3 moths

    Time frame: Change from baseline in peak oxygen uptake (ml/kg/min) at 3 months

Secondary outcomes

  1. 6-min walk test (6MWT) distance

    Changes in distance from the 6MWT.

    Time frame: Change from baseline to 3 months, and to 12 months.

  2. Health status (EQ-5D-5L)

    Health status will be evaluated by the 5-level EQ-5D version (EQ-5D-5L) questionnaire. The questionnaire comprises five dimensions, each describing a different aspect of health (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has five response levels of severity which range from 0 (no problems) to 5 (extreme problems/ unable to do). In addition, there is a score of overall health range from 0 to 100%.

    Time frame: Change from baseline to 3 months, and to 12 months.

  3. Health-related quality of life (MLHFQ)

    Health-related quality of life will be evaluated by the Minnesota Living with Heart Failure Questionnaire (MLHFQ). The MLHFQ is composed of 21 questions rated on a scale from 0 (no effect) to 5 (very much). The questionnaire is scored by summation of all 21 responses, where higher scores indicate worse quality of life.

    Time frame: Change from baseline to 3 months, and to 12 months.

  4. Anxiety and Depression (HADS)

    Anxiety and Depression will be evaluated by the Hospital Anxiety and Depression Scale (HADS). The questionnaire is composed of 14 questions on a four-point (0-3) scale. The possible scores ranged from 0 to 21 for anxiety and 0 to 21 for depression. A score of 0 to 7 for either subscale will be regarded as being in the normal range, a score of 11 or higher indicating probable presence of the mood disorder and a score of 8 to 10 being just suggestive of the presence of the respective state.

    Time frame: Change from baseline to 3 months, and to 12 months.

  5. Disutility

    Individual disutility (inconvenience) perceived by patients and respective quality of life gains. Longevity to offset the exercise program disutility will be expressed in days.

    Time frame: Evaluate at 3th month

  6. Physical activity (steps/day)

    Physical activity will be assessed by a POLAR-M200 device with the numbers of daily steps.

    Time frame: Change from baseline to 3 months, and to 12 months.

  7. Daily physical activity levels (min/day)

    Daily physical activity levels it will be measure with a POLAR-M200 device. Measures will be described as time spend in light physical activity, moderate and vigorous physical activity, and spend sitting or lying (minutes per day).

    Time frame: Change from baseline to 3 months, and to 12 months.

  8. Dyspnea

    Dyspnea will be evaluated by the Dyspnea-12 (D-12) questionnaire. The D-12 consists of 12 descriptor items on a scale of none (0), mild (1), moderate (2), or severe (3). It provides an overall score for breathlessness severity that incorporates seven physical items and five affective items. Total scores from the D-12 range from 0 to 36, with higher scores corresponding to greater severity.

    Time frame: Change from baseline to 3 months, and to 12 months.

  9. Mediterranean diet

    Adherence to Mediterranean diet will be evaluated by the 14-Item Mediterranean Diet Assessment Tool (MEDAS-14). The answer to each of the 14 items is scored with 1 in the case of meeting the criteria defined as typical of this type of food (range of possible variation 0-14 points). A total score ≥10 as represent a good adherence to the Mediterranean diet.

    Time frame: Change from baseline to 3 months, and to 12 months.

  10. Hand grip strength

    Hand grip strength will be assessed by Jamar dynamometer (kg)

    Time frame: Change from baseline to to 3 and to 12 months.

  11. Circulating number of endothelial progenitor cells, circulating endothelial cells, nitric oxide and endothelial Nitric Oxide Synthase

    These markers will inform endothelial function, damage and repair

    Time frame: Change from baseline to 3 months

  12. Biomarkers (pg/ml)

    NTproBNP and ST2 (pg/ml)

    Time frame: Change from baseline to 3 months

  13. Biomarkers (mg/L)

    hsCRP and Troponin (mg/L)

    Time frame: Change from baseline to 3 months

  14. Concentration of plasma exosomes

    Plasma exosomes will be isolated using microbead-based sorting techniques and characterized by nanoparticle tracking analysis, Western blot, and quantitative real-time polymerase chain reaction assessments

    Time frame: Change from baseline to 3 months

  15. Percentage of protein aggregates

    Protein aggregates (%) will be analysed using a diagonal two-dimensional (D2D) SDS-PAGE assay with mass spectrometry to identify and characterize detergent-resistant protein aggregates in plasma pre-cleared from albumin and immunoglobulin.

    Time frame: Change from baseline to 3 months

  16. Cost-effectiveness of home-based exercise Vs. clinical-base exercise

    Compare cost effectiveness analysis of home-based exercise Vs. clinical-base exercise. The main outcome measure for this study will be cost per quality adjusted life year (QALY)

    Time frame: At 12th month

  17. Physical fitness levels evaluation

    Physical fitness levels will be evaluated by the Senior Fitness test

    Time frame: Change from baseline to 3 and to 12 months.

Other outcomes

  1. Exploratory analyses of urine proteome

    Exploratory analyses in urine protein will be performed to identify novel biomarkers predictive of exercise training therapeutic response. Urine of 10 patients from each group will be analyzed using a proteomic approach combining one-dimensional gel electrophoresis with liquid chromatography-tandem mass spectrometry (GeLC-MS/MS). Generated proteomic data will be analyzed with bioinformatic tools to reveal possible biomarkers of interest, that will be further validated by immuno-approaches such as ELISA or immunoblot.

    Time frame: Change from baseline to 3 months

06

Study locations

1 site
  • Centro Hospitalar do Porto
    Porto, 4099-001, Portugal
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT04334603
Lead sponsor
Centro Hospitalar do Porto
Collaborators
Universidade do Porto, Aveiro University
Responsible party
Mário André Silva Santos (Cardiologist, MD, PhD, Centro Hospitalar do Porto) — Principal investigator
First posted
Apr 6, 2020
Start date
Nov 1, 2019
Primary completion
Dec 30, 2022
Completion
Dec 30, 2022
Last update
Feb 23, 2023

Study contacts

Mário Santos, MD,PhD
principal investigator · Cardiology Service of Centro Hospitalar do Porto

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion